Orthopediatrics Corp (KIDS)

Currency in USD
17.85
-0.01(-0.06%)
Closed·
17.850.00(0.00%)
·
KIDS is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
17.6218.43
52 wk Range
14.9123.70
Key Statistics
Prev. Close
17.86
Open
17.81
Day's Range
17.62-18.43
52 wk Range
14.91-23.7
Volume
216.21K
Average Vol. (3m)
148.71K
1-Year Change
-13.3074%
Book Value / Share
13.82
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
KIDS Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
24.89
Upside
+39.43%
Members' Sentiments
Bearish
Bullish
ProTips
Significant return over the last week

Orthopediatrics Corp News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity in children; and sports medicine and other products. Its products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail, PediLoc Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, Spica Tables, RESPONSE Spine, BandLoc, Pediatric Nailing Platform | Femur, Devise Rail, Orthex, The Fassier-Duval Telescopic Intramedullary System, SLIM Nail, The GAP Nail, The Free Gliding SCFE Screw System, GIRO Growth Modulation System, PNP Tibia System, ApiFix Mid-C System, Mitchell Ponseti, VerteGlideTM, and Boston Brace 3D. The company serves pediatric orthopedic market, as well as pediatric orthopedic surgeons and caregivers. OrthoPediatrics Corp. was founded in 2006 and is headquartered in Warsaw, Indiana.

Orthopediatrics Corp SWOT Analysis


Market Valuation
Analysts set a $50 price target, reflecting confidence in OrthoPediatrics' unique market position and growth strategy in the specialized pediatric orthopedic secto
Innovation Pipeline
Explore OrthoPediatrics' robust product development efforts, including delayed but promising launches of eLLi and VerteGlide, driving future growth potential
Financial Health
Company projects positive cash flow by 2026, with EBITDA margins expected to reach 13-14% by 2027, supported by a recent $100 million financing deal
Pediatric Orthopedics Pionee
OrthoPediatrics leads the underserved pediatric orthopedic market with impressive revenue growth and strategic expansion plans, targeting 71 markets by 2027
Read full SWOT analysis

Orthopediatrics Corp Earnings Call Summary for Q4/2025

  • OrthoPediatrics posted Q4 loss of $0.43/share, missing forecast of $0.30, but revenue rose 17% YoY to $61.6M, beating estimates of $59.51M.
  • Company achieved first-ever positive free cash flow quarter; gross margin improved 500 bps to 73%; adjusted EBITDA jumped 59% to $4.8M.
  • Stock climbed 6.4% to $16.72 in aftermarket trading despite EPS miss, reflecting investor confidence in revenue growth and strategic initiatives.
  • Management projects continued growth in 2026 with 3P Hip System launch, specialty bracing expansion, and European market penetration following approvals.
  • Key risks include supply chain disruptions, rising competition in pediatric orthopedics, regulatory changes, and currency fluctuations in international markets.
Last Updated: 02/26/2026, 05:29 PM
Read Full Transcript

Compare KIDS to Peers and Sector

Metrics to compare
KIDS
Peers
Sector
Relationship
P/E Ratio
−11.4x21.0x−0.5x
PEG Ratio
3.730.050.00
Price / Book
1.3x3.1x2.6x
Price / LTM Sales
1.9x3.5x3.2x
Upside (Analyst Target)
34.4%41.5%47.6%
Fair Value Upside
Unlock12.8%6.1%Unlock

Analyst Ratings

8 Buy
1 Hold
0 Sell
Ratings:
9 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 24.89
(+39.43% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Truist Securities
Hold20.00+12.04%19.00MaintainMar 02, 2026
Stifel
Buy22.00+23.25%20.00MaintainFeb 27, 2026
Needham
Buy30.00+68.07%26.00MaintainFeb 27, 2026
TD Cowen
Buy23.00+28.85%-New CoverageJan 27, 2026
Canaccord Genuity
Buy24.00+34.45%-New CoverageDec 10, 2025

Earnings

Latest Release
Feb 26, 2026
EPS / Forecast
-0.43 / -0.30
Revenue / Forecast
61.6M / 59.51M
EPS Revisions
Last 90 days

KIDS Income Statement

People Also Watch

0.714
GNTA
+11.28%
5.22
WEAV
+3.98%
5.91
FORR
+3.32%
2.510
DAIO
+2.45%
1.350
GIGM
-0.74%

FAQ

What Is the Orthopediatrics (KIDS) Stock Price Today?

The Orthopediatrics stock price today is 17.85 USD.

What Stock Exchange Does Orthopediatrics Trade On?

Orthopediatrics is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Orthopediatrics?

The stock symbol for Orthopediatrics is "KIDS."

What Is the Orthopediatrics Market Cap?

As of today, Orthopediatrics market cap is 451.23M USD.

What Is Orthopediatrics's Earnings Per Share (TTM)?

The Orthopediatrics EPS (TTM) is -1.69.

When Is the Next Orthopediatrics Earnings Date?

Orthopediatrics will release its next earnings report on May 06, 2026.

From a Technical Analysis Perspective, Is KIDS a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Orthopediatrics Stock Split?

Orthopediatrics has split 0 times.

How Many Employees Does Orthopediatrics Have?

Orthopediatrics has 602 employees.

What is the current trading status of Orthopediatrics (KIDS)?

As of Apr 16, 2026, Orthopediatrics (KIDS) is trading at a price of 17.85 USD, with a previous close of 17.86 USD. The stock has fluctuated within a day range of 17.62 USD to 18.43 USD, while its 52-week range spans from 14.91 USD to 23.70 USD.

What Is Orthopediatrics (KIDS) Price Target According to Analysts?

The average 12-month price target for Orthopediatrics is 24.89 USD, with a high estimate of 34 USD and a low estimate of 20 USD. 8 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +39.43% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.